$1.75 Million Risperdal Verdict Awarded to Maryland Man

On November 9, 2015, a Philadelphia jury ordered drug manufacturer Johnson & Johnson to pay 21-year-old Nicholas Murray $1.75 million after finding that the company’s antipsychotic drug Risperdal caused Murray to develop male breasts.

In the case, Murray alleged that J&J’s subsidiary, Janssen Pharmaceuticals, the company that manufactured the drug, failed to adequately warn patients and doctors of the risks of taking Risperdal, which included developing gynecomastia—a condition in which boys grow excessive breast tissue.

The case is the third to have a jury verdict in the approximately 1,500 cases pending in Pennsylvania state court concerning allegations that Risperdal caused abnormal breast growth.

The case is: Murray v. Janssen Pharmaceuticals Inc., No. 130401990, Court of Common Pleas, Philadelphia County (Philadelphia).

Counsel Financial provides working capital credit lines up to $5 million exclusively for the plaintiffs' bar in all states except California, where credit lines are issued by California Attorney Lending. Explore all of our financial solutions designed for contingent fee practice.